RESULTS There is sufficient evidence for a Grade A recommendation of the use of olanzapine plus fluoxetine at reducing depressive symptoms in bipolar depression and of quetiapine at high doses for depressive symptoms occurring during mixed episodes .
These results mostly overlap with the approved treatments for bipolar depression in adults
BACKGROUND The management of depressive and mixed symptoms in children and adolescents with bipolar disorder ( BD ) remains a matter of debate .
The goal of this review is , thus , to systematic ally examine the impact of atypical antipsychotics ( AAPs ) and mood stabilisers in the treatment of bipolar depression and /or mixed states .
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study.
OBJECTIVE To evaluate the efficacy and tolerability of ziprasidone in children and adolescents with Tourette 's syndrome and chronic tic disorders . METHOD Twenty-eight patients aged 7 to 17 years were r and omly assigned to ziprasidone or placebo for 56 days . Ziprasidone was initiated at a dose of 5 mg/day and flexibly titrated to a maximum of 40 mg/day . RESULTS Ziprasidone was significantly more effective than placebo in reducing the Global Severity ( p = .016 ) and Total Tic ( p = .008 ) scores on the Yale Global Tic Severity Scale . Compared with placebo , ziprasidone significantly reduced tic frequencies as determined by blind videotape tic counts ( p = .039 ) . The mean ( + /- SD ) daily dose of ziprasidone during the last 4 weeks of the trial was 28.2 + /- 9.6 mg . Mild transient somnolence was the most common adverse event . No clinical ly significant effects were observed on specific ratings of extrapyramidal symptoms , akathisia , or tardive dyskinesia . CONCLUSIONS In this limited sample , ziprasidone ( 5 - 40 mg/day ) appears to be effective and well tolerated in the treatment of Tourette 's syndrome . Ziprasidone may be associated with a lower risk of extrapyramidal side effects in children . However , additional studies are necessary to evaluate more fully its safety and efficacy in children with tic disorders
RESULTS There is sufficient evidence for a Grade A recommendation of the use of olanzapine plus fluoxetine at reducing depressive symptoms in bipolar depression and of quetiapine at high doses for depressive symptoms occurring during mixed episodes .
These results mostly overlap with the approved treatments for bipolar depression in adults
BACKGROUND The management of depressive and mixed symptoms in children and adolescents with bipolar disorder ( BD ) remains a matter of debate .
The goal of this review is , thus , to systematic ally examine the impact of atypical antipsychotics ( AAPs ) and mood stabilisers in the treatment of bipolar depression and /or mixed states .